- Home
- FULC vs LXEO Comparison
FULC vs LXEO Comparison
Compare FULC & LXEO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | FULC | LXEO |
|---|---|---|
| Founded | 2015 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 718.4M | 731.3M |
| IPO Year | 2019 | 2023 |
Fundamental Metrics
Financial Performance| Metric | FULC | LXEO |
|---|---|---|
| Price | $7.93 | $7.43 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 8 | 10 |
| Target Price | $16.38 | ★ $18.60 |
| AVG Volume (30 Days) | ★ 1.0M | 605.0K |
| Earning Date | 05-19-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 75.08 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $654,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.32 | $1.45 |
| 52 Week High | $15.74 | $10.99 |
Technical Indicators
Market Signals| Indicator | FULC | LXEO |
|---|---|---|
| Relative Strength Index (RSI) | 34.80 | 55.35 |
| Support Level | $6.33 | $6.90 |
| Resistance Level | $8.50 | $7.72 |
| Average True Range (ATR) | 0.80 | 0.46 |
| MACD | -0.17 | 0.13 |
| Stochastic Oscillator | 9.31 | 71.90 |
Price Performance
Historical ComparisonAbout FULC Fulcrum Therapeutics Inc.
Fulcrum Therapeutics Inc is a clinical-stage biopharmaceutical company. The company's programs in clinical development are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy (FSHD) and FTX-6058, a small molecule designed to increase expression of fetal hemoglobin for the treatment of sickle cell disease and other hemoglobinopathies, including beta-thalassemia.
About LXEO Lexeo Therapeutics Inc.
Lexeo Therapeutics Inc is a clinical-stage genetic medicines company committed to transforming healthcare by applying pioneering science to fundamentally alter how diseases are treated. The company focuses on preclinical and clinical stage gene therapies, specifically hereditary and acquired diseases with high unmet needs, which represent its sole business segment.